Investor News - No. 7 / 2016Notice of Zealand's interim report for the first nine months of 2016 and invitation to conference call
Copenhagen, 28 October 2016 - Zealand Pharma ("Zealand") confirms that it will release its interim report for the first nine months of 2016 on Wednesday 9 November 2016 in accordance with the company's financial calendar. The release is expected in the morning.
Zealand will going forward prepare interim reports in English only. A short version with key highlights and financial figures will be published in Danish.
Conference call on Wednesday 9 November 2016 at 2.00pm CET / 8.00am EDT
On the day of release, members of Zealand's senior management will host a conference call at 2.00pm CET to present the interim report for the first nine months of 2016. Participating in the call will be Britt Meelby Jensen, President and Chief Executive Officer, Mats Blom, SVP and Chief Financial Officer and Adam Steensberg, SVP and Chief Medical and Development Officer.
The presentation will be followed by a Q&A session.
The conference call will be conducted in English and the dial-in numbers are:
DK standard access +45 38 32 28 69
UK and international +44 (0) 20 3427 1906
US (free dial-in) +1 646 254 3362
Kindly inform the operator of one of the following passcodes: "Zealand Pharma" or 9968202.
A live audio webcast of the call including an accompanying slide presentation will be available via the following link: http://edge.media-server.com/m/p/spwqjphn , accessible also from the company's website ( www.zealandpharma.com ). Participants are advised to register for the webcast approximately 10 minutes before the start.
A replay of the event will be made available from the Investor section of Zealand's website following the call.
For further information, please contact:
Senior Vice President, Chief Financial Officer
Tel: +45 31 53 79 73, email: firstname.lastname@example.org
About Zealand Pharma A/S
Zealand Pharma A/S (Nasdaq Copenhagen: ZEAL) ("Zealand") is a biotechnology company focused on the discovery, design and development of innovative peptide-based medicines. Zealand has a portfolio of medicines and product candidates under license collaborations with Sanofi, Boehringer Ingelheim and Helsinn and a pipeline of proprietary product candidates, which primarily target specialty diseases with significant unmet needs.
The company's first invented medicine, lixisenatide, a once-daily prandial GLP-1 analog for the treatment of type 2 diabetes, is licensed to Sanofi. Lixisenatide is marketed as Lyxumia ® outside the United States and approved as Adlyxin TM in the United States. Lixisenatide has been developed in a fixed-ratio combination with Lantus ® (insulin glargine) which product is under regulatory review in the United States and in Europe.
Zealand's proprietary pipeline includes: Dasiglucagon * (ZP4207) as single-dose rescue treatment for acute, severe hypoglycemia (Phase II); Glepaglutide* (ZP1848) for treatment of short bowel syndrome (Phase II); Dasiglucagon* (ZP4207) multiple-dose version intended for use in a dual-hormone artificial pancreas system for better hypoglycemia control and diabetes management (in preparation for Phase II); and other earlier stage clinical and preclinical peptide therapeutics.
Zealand is based in Copenhagen (Glostrup), Denmark. For further information about the company's business and activities, please visit www.zealandpharma.com or follow Zealand on Twitter @ZealandPharma.
* Dasiglucagon and glepaglutide are proposed International Nonproprietary Names (pINN)07-16_1028 Notice of interim report for 9m 2016 and TC
Last updated on: 30/10/2016
PharmiWeb.com is Europe's leading industry-sponsored portal for the Pharmaceutical sector, providing the latest jobs, news, features and events listings.
The information provided on PharmiWeb.com is designed to support, not replace, the relationship that exists between a patient/site visitor and his/her physician.